Therapeutic effects of lactobacillus in treating irritable bowel syndrome: A meta-analysis

Internal Medicine

Volumn 54, Issue 3, 2015, Pages 243-249

  Tiequn, Bian ^a   Guanqun, Chao ^b   Shuo, Zhang ^c  

^a Xiaoshan Traditional Chinese Medical Hospital   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

Irritable bowel syndrome; Lactobacillus; Meta analysis

Indexed keywords

BIOLOGICAL PRODUCT; DRUG THERAPY; PLACEBO; PROBIOTIC AGENT;

ADULT; ARTICLE; ASSESSMENT OF HUMANS; BIBLIOGRAPHIC DATABASE; CHILD; CONTROLLED CLINICAL TRIAL (TOPIC); DIET THERAPY; EVIDENCE BASED MEDICINE; FEMALE; GASTROINTESTINAL TRACT; HUMAN; IMMUNOLOGY; IRRITABLE COLON; JADAD SCORE; LACTOBACILLUS; MALE; META ANALYSIS; OUTCOME ASSESSMENT; PUBLISHING; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADULT; CHILD; DIET THERAPY; EVIDENCE-BASED MEDICINE; FEMALE; GASTROINTESTINAL TRACT; HUMANS; IMMUNOLOGY; IRRITABLE BOWEL SYNDROME; LACTOBACILLUS; MALE; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THERAPEUTIC USE; TREATMENT OUTCOME;

EID: 84964199934     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.54.2710     Document Type: Article

References (26)

1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 130: 1480-1491, 2006.
2. Camilleri M, Coulie B, Tack JF. Visceral hypersensitivity facts, speculations, and challenges. Gut 48: 125-131, 2001.
3. Camilleri M. Management of the irritable bowel syndrome. Gastroenterology 120: 652-668, 2001.
4. Clouse RE. Managing functional bowel disorders from the top down: lessons from a well-designed treatment trial. Gastroenterology 125: 249-253, 2003.
5. Joint FAO/WHO Working Group. Report on Drafting Guidelines for the Evaluation of Probiotics in Food. London, Ontario, Canada, April 30 and May 1, 2002.
6. Floch MH, Madsen KK, Jenkins DJ, et al. Recommendations for probiotic use. J Clin Gastroenterol 40: 275-278, 2006.
7. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 14: 2650-2661, 2008.
8. Nikfar S, Rahimi R, Rahimi F, et al. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum 51: 1775-1780, 2008.
9. Hoveyda N, Heneghan C, Mahtani KR, et al. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 9: 15, 2009.
10. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. Gut 59: 325-332, 2010.
11. Sinn DH, Song JH, Kim HJ, et al. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci 53: 2714-2718, 2008.
12. Huertas-Ceballos AA, Logan S, Bennett C, Macarthur C. Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in child-hood. Cochrane Database of Syst Rev 1: CD003019, 2009.
13. Vader JP. Randomised controlled trials: a user’s guide. BMJ 317: 1258, 1998.
14. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101, 1994.
15. Egger M, Davey SG, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ 315: 629-634, 1997.
16. Bausserman M, Michail S. The use of Lactobacillus GG in irritable bowel syn-drome in children: a double-blind randomized control trial. J Pediatr 147: 197-201, 2005.
17. Gawronska A, Dziechciarz P, Horvath A, Szajewska H. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther 25: 177-184, 2007.
18. Francavilla R, Miniello V, Magistà AM, et al. A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain. Pediatrics 126: e1445-e1452, 2010.
19. Zeng J, Li YQ, Zuo XL, Zhen YB, Yang J, Liu CH. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 28: 994-1002, 2008.
20. Ducrotté P, Sawant P, Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol 18: 4012-4018, 2012.
21. Forbes AL, Hunter JO. Irritable bowel syndrome. Medicine 35: 267-271, 2007.
22. Mertz HR. Irritable bowel syndrome. N Engl J Med 349: 2136-2146, 2003.
23. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 104 (Suppl 1): S1-S35, 2009.
24. Jones J, Boorman J, Cann P, et al. British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome. Gut 47 (Suppl 2): ii1-ii19, 2000.
25. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 130: 1480-1491, 2006.
26. Camilleri M. Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy. J Clin Gastroenterol 40: 264-269, 2006.